USPTO serial 78219523
POTELLIGENT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 23, 2007
- Examiner
- GRIFFIN, JAMES
- Law office
- TMEG LAW OFFICE 103
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with POTELLIGENT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
TOKYO, JP
CHIYODA-KU, TOKYO, JP
Tokyo, JP
Tokyo, JP
Tokyo, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal R. Odedra
Kaushal R. Odedra ODEDRA LAW OFFICE, PLLC2020 Pennsylvania Ave, NW #152Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical research; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical research ] | SECTION 8 - CANCELLED | — |
| 005 | [ Cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers, and antianxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, mucolytic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases ] | SECTION 8 - CANCELLED | — |
| 040 | Contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KYOWA KIRIN CO., LTD.
- Other trademarks owned by KYOWA HAKKO KIRIN CO., LTD.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Similar marks named POTELLIGENT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 23, 2026 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Sep 4, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 17, 2017 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Mar 17, 2017 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Mar 17, 2017 | 9G8P | REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8 | — |
| Mar 17, 2017 | 8PRT | REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED | — |
| Mar 17, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 20, 2017 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Jul 9, 2013 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED | — |
| Jul 9, 2013 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jul 9, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 23, 2013 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Nov 19, 2008 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 23, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 5, 2006 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Nov 30, 2006 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Nov 30, 2006 | FAXX | FAX RECEIVED | — |
| Oct 17, 2006 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 25, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 5, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 1, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 26, 2006 | ALIE | ASSIGNED TO LIE | — |
| May 24, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 24, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 17, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 17, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2006 | CNCF | CONTINUATION OF FINAL REFUSAL MAILED | — |
| Apr 27, 2006 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Apr 27, 2006 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Apr 27, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 27, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 21, 2006 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 6, 2006 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 3, 2006 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 9, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Feb 7, 2006 | PAPER RECEIVED | — | |
| Feb 3, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 3, 2006 | PAPER RECEIVED | — | |
| Oct 18, 2005 | CRML | CORRESPONDENCE MAILED | — |
| Oct 18, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 19, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 19, 2005 | PAPER RECEIVED | — | |
| May 13, 2005 | CNSL | LETTER OF SUSPENSION MAILED | — |
| May 12, 2005 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 10, 2005 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 2, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 2, 2005 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2004 | CNSI | INQUIRY AS TO SUSPENSION MAILED | — |
| Nov 19, 2004 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Mar 26, 2004 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Feb 9, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 9, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 19, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2003 | DOCK | ASSIGNED TO EXAMINER | — |